This case study presents a legal counsel memorandum prepared for Marcus Welby Healthcare Corporation (MWHC), examining four potentially fraudulent practices carried out by one of its subsidiaries. The practices under review include offering financial incentives to home health agency employees tied to durable medical equipment (DME) orders, providing rebates to patients, selectively compensating hospital staff for product training, and allegedly falsifying medical test results to qualify for Medicare reimbursement. Drawing on federal compliance standards enforced by the HHS Office of Inspector General, the memo outlines MWHC's respondeat superior liability and issues specific cease-and-desist recommendations to mitigate criminal, civil, and financial exposure.
This memorandum is prepared for the Legal Counsel of Marcus Welby Healthcare Corporation (MWHC) and addresses four areas of potential fraud and abuse identified within a subsidiary's operations.
According to the information provided, a subsidiary of MWHC has been offering its contracted home health agency employees premiums in connection with client durable medical equipment (DME) orders from the subsidiary. Additionally, the subsidiary offers financial rebates to patients who use its equipment. The subsidiary also pays hospital and home health agency personnel for assisting its patients in learning how to use its products. Finally, there is objective data suggesting that various test results may have been deliberately altered or fabricated for the purpose of qualifying for federal fund reimbursement from the Medicare program.
Marcus Welby Healthcare Corporation, much the same as other medical service providers in the United States, is eligible for certain federal financial reimbursement for some of the costs of the services it renders to Medicare and Medicaid-eligible beneficiaries. To minimize the potential abuse of federal reimbursement programs, the U.S. Department of Health and Human Services (HHS) maintains strict compliance protocols, through which it monitors, investigates, and enforces compliance via the Office of Inspector General (USDHHS, 2004).
Partly for that reason, most medical providers and other recipients of federal funds establish and maintain very strict compliance protocols to avoid any improprieties or potential fraud involving federal reimbursement programs. Considering that Medicare and Medicaid fraud currently amounts to as much as $100 billion dollars annually (Reid, 2009), that concern is understandable. Generally, all healthcare and healthcare educational institutions establish very strict compliance protocols in that regard, as well as comprehensive ethical guidelines to ensure against both actual conflicts of interest and any apparent conflicts or improprieties — as illustrated by the Boonshoft School of Medicine Pharmaceutical/Medical Device Industry Conflict of Interest Policy (WSU, 2008).
"MWHC's legal exposure for subsidiary misconduct"
"Four cease-and-desist directives to eliminate fraud risk"
You’re 47% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.